deltatrials
Completed PHASE3 NCT00014534

Combination Chemotherapy in Treating Patients With Bladder Cancer

Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Bladder Cancer
Interventions cisplatin doxorubicin hydrochloride filgrastim gemcitabine hydrochloride
Updated 7 times since 2017 Last updated: Jul 12, 2016 Started: Mar 31, 2004 Primary completion: Jul 31, 2005 Completion: Apr 30, 2009

Listed as NCT00014534, this PHASE3 trial focuses on Bladder Cancer and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albany, United States, Altanta, United States, Ames, United States, Anderson, United States, Ann Arbor, United States, Appleton, United States, Arroyo Grande, United States, Asheboro, United States, Athens, United States and 182 more location s